Because PD-L1 expression on host cells also affects the anti-tumor activity of anti-PD-L1 immunotherapy [31, 32], we investigated the effect of low-dose TSA on PD-L1 expression on immune cells, especially myeloid cells in the TME. Here, CD274 is linked to neoplasm.